Moving seasonal malaria chemoprevention out of its geographical isolation
Cabamiquine, which was previously known as DDD107498 or M5717, is a novel antimalarial drug that has been shown to be very effective against multiple stages of the life cycle of Plasmodium falciparum at low drug concentrations. Cabamiquine targets the P falciparum translation elongation factor 2 (PfeEF2) essential for the protein synthesis of the parasite.
In their Article in The Lancet Infectious Diseases, van der Plas and colleagues present the results of a phase 1b, randomised, double-blind, placebo-controlled, adaptive, dose-finding study of cabamiquine to evaluate its chemoprophylactic potential against malaria infection in healthy, malaria-naive adults.
Read the full article on the Science Direct website.